Rasonque authorised in the EU: what PV teams can and cannot yet say about daraxonrasib
The Commission has authorised Revolution Medicines' Rasonque, but the Union Register entry gives no indication or conditions, so PV planning must wait on documents not yet in view.
What happened
On 16 November 2026 the European Commission's Union Register recorded a marketing authorisation for Rasonque (daraxonrasib). The holder is Revolution Medicines Netherlands B.V.
The register entry is thin. It does not state the indication, and it does not say whether the authorisation carries conditions. Any commentary on Rasonque's therapeutic use, its safety profile or its post-authorisation obligations would therefore go beyond the record. This article does not offer any. What it can do is set out what a newly authorised product means for pharmacovigilance in general terms, and what to check once fuller documents are available.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- Commission grants marketing authorisation for Revolution Medicines' daraxonrasib product Rasonque European Commission (Union Register) · Mon 16 Nov 2026
- Pleasanton drug discovery firm Cyion to pay $528,336 over alleged False Claims Act grant violations HHS OIG · Mon 16 Nov 2026
- Real4Reg final symposium at Infarmed showcases real-world data studies and free training INFARMED · Mon 16 Nov 2026
- Baltic paper-free leaflet project to continue after 2026 with Commission's backing Ravimiamet · Mon 16 Nov 2026
- Medline details repair and replace programme for recalled beds, rails, mattresses and accessories FDA MedWatch · Fri 13 Nov 2026
- PRAC publishes final EU-language translations of phenobarbital product information in targeted signal procedure EMA · PRAC · Fri 13 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.